Yusuke Tanigawara
Yusuke Tanigawara, Tokyo JP
Patent application number | Description | Published |
---|---|---|
20100323034 | METHOD FOR DETERMINATION OF SENSITIVITY TO ANTI-CANCER AGENT - Provided are an marker for determining sensitivity to an anticancer agent capable of distinguishing a therapeutic response of an individual patient and a novel means for a cancer therapy using the marker. The marker for determining sensitivity to an anticancer agent contains a calcium-binding protein S100A7, S100A8, or S100A10. | 12-23-2010 |
20110003842 | MARKER FOR DETERMINATION OF SENSITIVITY TO ANTI-CANCER AGENT - Provided are a marker for determining sensitivity to an anticancer agent capable of distinguishing a therapeutic response of an individual patient and a novel means for a cancer therapy using the marker. The marker for determining sensitivity to an anticancer agent contains a substance in a metabolic pathway in which L-phenylalanine and/or N,N-dimethyl glycine are/is involved. | 01-06-2011 |
20120214831 | METHOD FOR DETERMINATION OF SENSITIVITY TO ANTI-CANCER AGENT - To provide a marker for determining sensitivity of a patient to an anti-cancer agent, and novel cancer therapeutic means employing the marker. | 08-23-2012 |
20120220613 | METHOD FOR DETERMINING SENSITIVITY TO AN ANTICANCER AGENT - To provide a marker for determining sensitivity of a patient to an anti-cancer agent, and novel cancer therapeutic means employing the marker. | 08-30-2012 |
20120220618 | ANTICANCER AGENT SENSITIVITY-DETERMINING MARKER - To provide a marker for determining sensitivity of a patient to an anti-cancer agent, and novel cancer therapeutic means employing the marker. | 08-30-2012 |
Yusuke Tanigawara, Kanagawa JP
Patent application number | Description | Published |
---|---|---|
20090053695 | Gene Marker and Use Thereof | 02-26-2009 |
20090162868 | Gene Markers and Utilization of the Same - [Problems]To provide a gene marker which enables diagnosis of rejection, evaluation of the efficacy of an immunosuppressive agent, and determination of the presence or absence of immunological tolerance; methods that can be performed in a quick, simple, and convenient manner by using the gene marker as an indicator for diagnosing rejection, evaluating the efficacy of an immunosuppressive agent, identifying an immunosuppressive agent, selecting an immunosuppressive agent, determining the dose of an immunosuppressive agent, and judging the presence or absence of immunological tolerance; a kit; and a method for screening for an immunosuppressive agent or an immunological tolerance-inducing agent. | 06-25-2009 |
Yusuke Tanigawara, Kawasaki-Shi JP
Patent application number | Description | Published |
---|---|---|
20140107068 | MARKER FOR DETERMINATION OF SENSITIVITY TO ANTICANCER AGENT - A marker can determine whether or not a patient has a therapeutic response to an anti-cancer agent. A novel cancer therapy employs the marker. The marker can be N-acetylglucosamine, an amino-acid-metabolism-related substance, a nucleic-acid-metabolism-related substance, a substance in the pentose phosphate pathway, a substance in the glycolytic pathway, a substance in the TCA cycle, a polyamine-metabolism-related substance, lauric acid, 6-phosphogluconic acid, butyric acid, 4-methylpyrazole, isobutylamine, glycolic acid, NADH, NAD | 04-17-2014 |
Yusuke Tanigawara, Shinjuku-Ku JP
Patent application number | Description | Published |
---|---|---|
20150038522 | COMBINED ANTICANCER DRUG SENSITIVITY-DETERMINING MARKER - To provide an anti-cancer agent sensitivity determination marker, which marker can determine whether or not the patient has a therapeutic response to the anti-cancer agent, and novel cancer therapeutic means employing the marker. | 02-05-2015 |